SABS

SAB Biotherapeutics, Inc. (SABS) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG). The company's lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) designed to prevent or delay the progression of Type 1 Diabetes (T1D). The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to $0 in Q3 2024 from $1.27M in Q3 2023, and decreased 37.6% year-over-year for the nine-month period. This is primarily due to the termination of the JPEO Rapid Response Contract in 2022 and the completion of NIH-NIAID grants in mid-2023.
• Increased Operating Expenses:
  • R&D Expenses: Increased 94.8% QoQ (3-month) and 85.0% YTD. Drivers include higher clinical trial costs ($1.46M in Q3 vs $0.21M prior year), outside laboratory services, and salaries.
  • G&A Expenses: Increased 35.3% QoQ and 29.1% YTD, driven by increased headcount and professional fees.
• Non-Operating Income: Significant non-cash gain of $7.69M YTD 2024 from the change in fair value of warrant liabilities, compared to a loss of $96k in the prior year. This reduced the reported net loss significantly.
• Liquidity Position: Cash and cash equivalents decreased from $56.6M at year-end 2023 to $9.2M at Q3 2024. However, the company holds $21.2M in short-term investments, bringing total liquid assets to approximately $30.4M.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management states that current cash and short-term investments ($30.4M) are not sufficient to fund operations for more than 12 months from the date of issuance. This raises substantial doubt about the company's ability to continue as a going concern without additional financing.
• Clinical Progress: SAB-142 Phase 1 enrollment in healthy volunteers is complete. The company is progressing to enroll T1D patients and expects a topline Phase 1 data readout by the end of 2024. A Phase 2 SAFEGUARD study is anticipated to begin in early 2025.
• Capital Needs: The company intends to seek additional capital through equity or debt financings. Failure to raise capital could force the company to scale back operations, reduce headcount, or cease operations.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to a material weakness in the control environment regarding documentation of financial reporting processes. Remediation efforts are underway with a third-party firm.
• Warrant Liabilities: The company has significant warrant liabilities ($4.08M) classified as Level 3 fair value measurements, which fluctuate based on stock price and volatility assumptions.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $30.4M in liquid assets against the current burn rate (approx. $10M net loss per quarter, though non-cash items like warrant valuation changes affect this).
• Financing Plans: Monitor for announcements regarding new equity offerings, debt financing, or strategic partnerships to address the going concern warning.
• Clinical Milestones: Track the timeline for the SAB-142 Phase 1 topline data readout (expected late 2024) and the initiation of the Phase 2 SAFEGUARD study.
• Internal Control Remediation: Confirm the completion of remediation for the material weakness in internal controls over financial reporting by the end of 2024.
• Warrant Liability Volatility: Note that net income/loss is heavily influenced by non-cash changes in the fair value of warrant liabilities, which can distort operating performance metrics.